GLP1 receptor (GLP1R)
Our GLP1R fluorescent ligands have been tested extensively in a range of cell lines and have been found to be highly specific for the GLP-1 receptor. They are ideal for studying the GLP1 receptor in various contexts, including the study of type 2 diabetes, weight loss, and kidney disease. As a market leader in fluorescent ligand development, we are uniquely positioned to supply high-quality GLP1R solutions with high affinity for the GLP-1 receptor, making them ideal for various applications, including live cell imaging, receptor activation assays, and more.
LUXendins have been developed by Johannes Broichhagen (Max Planck Institute for Medical Research, Heidelberg, Germany and Leibniz-Forschungsinstitut für Molekulare Pharmakologie, Berlin, Germany) and David J. Hodson (University of Birmingham), and are exclusively licensed to Celtarys for commercialization. These ligands have been shown to be highly effective in studying the GLP-1 receptor and related proteins, including glucagon-like peptide and GLP-1 receptor agonists. The ligands are also highly effective in studying the nervous system, blood sugar levels, and cell surface signaling pathways. They have been shown to be highly effective in binding to the receptor, activating it, and studying its downstream effects.
At Celtarys, we are committed to providing you with the best products on the market for studying G protein-coupled receptors, and we are constantly developing new solutions to meet your needs.
Showing all 3 results
-
LUXendin551 GLP1 receptor (GLP1R) fluorescent antagonist (551/576) (CELT-111)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more -
LUXendin645 GLP1 receptor (GLP1R) fluorescent antagonist (645/664) (CELT-112)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more -
LUXendin762 GLP1 receptor (GLP1R) fluorescent antagonist (762/784) (CELT-113)
For research use only3 nmol vial that allows to prepare 30 µL of 100 µM stock solution to test GLP1R. One vial is sufficient for injecting one mouse.
Please note that the required concentration may vary depending on the specific assay design.
424,00€ View more
PERTE SALUD Proyecto Nº: IDI-2025-0751
Título: TERAPIAS AVANZADAS EN INMUNOONCOLOGÍA: UNA ESTRATEGIA INNOVADORA
BASADA EN LA DEGRADACIÓN DIRIGIDA DE GPCR EN EL EJE ADENOSINÉRGICOS
EIC Pathfinder; Project name: Unisens; Universal GPCR Activity Sensor for Next Generation Drug Discovery
Esta entidad fue beneficiaria de las ayudas para la ejecución de acciones de promoción exterior de las empresas gallegas. El objetivo principal de estas ayudas es incentivar la realización de acciones de promoción exterior generadoras de ventajas competitivas. El resultado que se pretende conseguir es el impulso de las pymes y sus productos y servicios, aumentando el número de empresas de base exportadora.
Celtarys Research is beneficiary of a WomenTechEU grant supporting deep-tech start-ups led by women
Principia 2021 Program
Celtarys staff has been funded by the Xunta de Galicia within the framework of the PRINCIPIA 2021 Program of the Galician Innovation Agency (GAIN)
InnovaPEME Program
Celtarys Innovation Plan has been funded by the InnovaPEME 2022 program of the Galician Innovation Agency (GAIN)
Bonos de Innovación de Celtarys Research (026)
Para promover o desenvolvemento tecnolóxico, a innovación e unha investigación de calidade. Esta operación está financiada pola Xunta de Galicia, a través de axudas concedidas pola Axencia Galega de Innovación, dentro do programa de axudas a empresa Bonos de innovación 2022.
Celtarys Research is part of the public-private consortium developing the project PREDICTEAM
New prognostic quantitative biomarker assays for predicting patient response to immune checkpoint inhibitor (ICI) treatment
NEOTEC · CDTI — Ministerio de Ciencia e Innovación
The Project ‘New chemical conjugation technology for therapeutic targets’ has been founded by CDTI under its program NEOTEC. The NEOTEC program objective is supporting the establishment and consolidation of technology-based enterprises. A technology-based company (EBT) is a company whose activity focuses on the exploitation of products or services that require the use of technologies and knowledge developed since the research activity. The EBT base their business strategy or activity in the intensive domain of scientific and technical knowledge. Budget awarded: 416.177€ | Execution dates: 1/1/2023 – 31/03/2024